Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | NFE2L2 | Q16236 | 8/20 | 0.42 |
| ▸ | IDO1 | P14902 | 2/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Boric Acid SCHEMBL29277889 | 0.91 | ACHE (0.37) | ACHENFE2L2IDO1CES2CES1 | |
| Phosphoric Acid SCHEMBL29277885 | 0.87 | GAA (0.38) | ACHENFE2L2CES2CES1NPC1 | |
| SCHEMBL1880902 | 0.85 | IDO1 (0.41) | ACHEIDO1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL29726936 | 0.85 | IDO1 (0.41) | ACHEIDO1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL15091550 | 0.81 | ACHE (0.42) | ACHENFE2L2NOTUMCES2CES1 | |
| SCHEMBL18692020 | 0.79 | ACHE (0.46) | ACHENFE2L2NOTUMCES2CES1 | |
| SCHEMBL713563 | 0.79 | CES2 (0.38) | ACHEIDO1CES2CES1 | |
| SCHEMBL13621359 | 0.77 | ACHE (0.39) | ACHENFE2L2IDO1NOTUMCES2 | |
| Hydrochloric Acid SCHEMBL19405531 | 0.75 | ACHE (0.37) | ACHENFE2L2NOTUMNPC1GAA | |
| Bromide SCHEMBL19405535 | 0.75 | ACHE (0.37) | ACHENFE2L2NOTUMNPC1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114797808-A | Fluorine-containing liquid chromatography packing for polar drug separation and preparation method thereof | 烟台大学 | 2022-07-29 | — | — | CN | claimed |
| CN-108084013-B | Synthetic method of 3-bromo-2-fluorobenzoic acid | 蓬莱市前卫化工有限公司 | 2020-09-01 | — | — | CN | claimed |
| CN-108084013-A | A kind of synthetic method of the bromo- 2- fluobenzoic acids of 3- | 上海晋鲁医药科技有限公司 | 2018-05-29 | — | — | CN | claimed |
| CN-114797808-B | Fluorine-containing liquid chromatography packing for polar medicine separation and preparation method thereof | 烟台大学 | 2024-03-22 | — | — | CN | disclosed |
| CN-114797808-A | Fluorine-containing liquid chromatography packing for polar drug separation and preparation method thereof | 烟台大学 | 2022-07-29 | — | — | CN | disclosed |
| CN-108084013-B | Synthetic method of 3-bromo-2-fluorobenzoic acid | 蓬莱市前卫化工有限公司 | 2020-09-01 | — | — | CN | disclosed |
| CN-108084013-B | Synthetic method of 3-bromo-2-fluorobenzoic acid | 蓬莱市前卫化工有限公司 | 2020-09-01 | — | — | CN | disclosed |
| CN-108084013-A | A kind of synthetic method of the bromo- 2- fluobenzoic acids of 3- | 上海晋鲁医药科技有限公司 | 2018-05-29 | — | — | CN | disclosed |
| CN-108084013-A | A kind of synthetic method of the bromo- 2- fluobenzoic acids of 3- | 上海晋鲁医药科技有限公司 | 2018-05-29 | — | — | CN | disclosed |
| CN-108003016-A | A kind of synthetic method of the bromo- 3- fluobenzoic acids of 2- | 上海晋鲁医药科技有限公司 | 2018-05-08 | — | — | CN | disclosed |
| EP-3018123-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-05-11 | — | — | EP | disclosed |
| US-20080194816-A1 | Method of producing an o-disubstituted aromatic compound, and method of producing a monosubstituted-monohaloaromatic compound | FUJIFILM CORPORATION (JP) | 2008-08-14 | — | — | US | disclosed |
| CN-1043575-C | Silylated acetylcholinesterase inhibitors | MERRELL DOW PHARMA (US) | 1999-06-09 | — | — | CN | disclosed |
| EP-0684951-B1 | SILYLATED ACETYLCHOLINESTERASE INHIBITORS | MERRELL PHARMA INC (US) | 1997-05-07 | — | — | EP | disclosed |
| US-5523442-A | TREATING ALZHEIMER'S, DEMENTIA | MERRELL PHARMACEUTICALS INC. (US) | 1996-06-04 | — | — | US | disclosed |
| CN-1117733-A | Silylated acetylcholinesterase inhibitors | MERRELL DOW PHARMA (US) | 1996-02-28 | — | — | CN | disclosed |
| EP-0684951-A1 | SILYLATED ACETYLCHOLINESTERASE INHIBITORS. | MERRELL DOW PHARMA (US) | 1995-12-06 | — | — | EP | disclosed |
| WO-1994019356-A1 | SILYLATED ACETYLCHOLINESTERASE INHIBITORS | MERRELL DOW PHARMACEUTICALS INC. (US) | 1994-09-01 | — | — | WO | disclosed |
| EP-0611769-A1 | Silylated acetylcholinesterase inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1994-08-24 | — | — | EP | disclosed |
| EP-0349373-A2 | Process for the preparation of ortho-substituted fluoro or alkyl benzene derivatives | RHONE-POULENC CHIMIE (FR) | 1990-01-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194816-A1 | Method of producing an o-disubstituted aromatic compound, and method of producing a monosubstituted-monohaloaromatic compound | DDT, OXER1, OSTC | ACHE 2841/4885NFE2L2 1732/4885IDO1 2098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.